StockNews.AI
CODX
StockNews.AI
19 days

Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

1. Co-Diagnostics will release Q2 2025 results on August 14, 2025. 2. A conference call will follow to discuss financial results with analysts. 3. Management includes the CEO, CFO and Head of Investor Relations.

4m saved
Insight
Article

FAQ

Why Neutral?

While scheduled earnings can cause volatility, there's no preceding data indicating significant changes for CODX. Historical earnings releases have shown mixed responses; some positively impacted the stock while others did not.

How important is it?

Upcoming earnings release is essential for current investors. Positive results could improve market sentiment; if negative, could lead to a downturn.

Why Short Term?

Results will be revealed in the near term, directly affecting investor sentiments and stock movements.

Related Companies

QDELGHDXBHTG
, /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here Conference Call: 888-880-3330 (Toll Free) or (646) 357-8766 (Toll) If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc.Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. SOURCE Co-Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News